Literature DB >> 24499107

Sphingosine 1-phosphate: a potential molecular target for ovarian cancer therapy?

Lan Dai1, Pu Xia, Wen Di.   

Abstract

Sphingosine 1-phosphate (S1P) is an important signaling regulator involved in tumor progression in multiple neoplasms. However, the role of S1P in the pathogenesis of ovarian cancer remains unclear. Herein, we summarize recent advances in understanding the impact of S1P signaling in ovarian cancer progression. S1P, aberrantly produced in ovarian cancer patients, is involved in the regulation of key cellular processes that contribute to ovarian cancer initiation and progression. Moreover, agents that block the S1P signaling pathway inhibit ovarian cancer cell growth or induce apoptosis. Hence, current evidence suggests that S1P may become a potential molecular target for ovarian cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24499107     DOI: 10.3109/07357907.2013.876646

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  16 in total

Review 1.  Potential microRNA-related Targets for Therapeutic Intervention with Ovarian Cancer Metastasis.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwen Kollmorgen; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2018 Jan-Feb       Impact factor: 4.069

2.  Ultrasound-stimulated microbubble enhancement of radiation treatments: endothelial cell function and mechanism.

Authors:  Azza A Al-Mahrouki; Emily Wong; Gregory J Czarnota
Journal:  Oncoscience       Date:  2015-12-15

3.  Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis.

Authors:  Lan Dai; Yixuan Liu; Lei Xie; Xia Wu; Lihua Qiu; Wen Di
Journal:  Oncotarget       Date:  2017-08-24

4.  Sphingosine-1-phosphate promotes ovarian cancer cell proliferation by disrupting Hippo signaling.

Authors:  Qianlan Fan; Yuan Cheng; Hsun-Ming Chang; Masashi Deguchi; Aaron J Hsueh; Peter C K Leung
Journal:  Oncotarget       Date:  2017-04-18

Review 5.  Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget.

Authors:  Diana Hatoum; Nahal Haddadi; Yiguang Lin; Najah T Nassif; Eileen M McGowan
Journal:  Oncotarget       Date:  2017-05-30

Review 6.  Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2018-07-09       Impact factor: 6.639

Review 7.  Histone deacetylases as new therapy targets for platinum-resistant epithelial ovarian cancer.

Authors:  Dmitri Pchejetski; Albandri Alfraidi; Keith Sacco; Heba Alshaker; Aun Muhammad; Leonardo Monzon
Journal:  J Cancer Res Clin Oncol       Date:  2015-11-11       Impact factor: 4.553

8.  High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism.

Authors:  Elena Ioana Braicu; Silvia Darb-Esfahani; Wolfgang D Schmitt; Kaisa M Koistinen; Laura Heiskanen; Päivi Pöhö; Jan Budczies; Marc Kuhberg; Manfred Dietel; Christian Frezza; Carsten Denkert; Jalid Sehouli; Mika Hilvo
Journal:  Oncotarget       Date:  2017-10-26

9.  Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.

Authors:  Shushu Wang; Yueyang Liang; Wenxiao Chang; Baoquan Hu; Yi Zhang
Journal:  Med Sci Monit       Date:  2018-04-01

10.  First evidence of SGPL1 expression in the cell membrane silencing the extracellular S1P siren in mammary epithelial cells.

Authors:  Nadja Engel; Anna Adamus; Marcus Frank; Karin Kraft; Juliane Kühn; Petra Müller; Barbara Nebe; Annika Kasten; Guido Seitz
Journal:  PLoS One       Date:  2018-05-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.